Reaction

Tumour Marker Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,748 reports · 89 co-occurring drugs

As of the last recalculation, Tumour Marker Increased appears in 4,748 FAERS reports alongside 89 co-occurring drug terms. The strongest observed disproportionality signal is RUCAPARIB (PRR 135.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rucaparib	259	135.9	140.0
Fulvestrant	666	102.6	104.7
Niraparib	360	76.9	78.1
Exemestane	262	56.7	57.4
Ribociclib	341	50.9	51.5
Palbociclib	873	48.9	49.4
Letrozole	565	45.5	45.9
Letrozole Tablets	416	41.5	41.8
Alpelisib	81	41.4	41.8
Olaparib	185	40.3	40.7
Anastrozole Tablets	154	32.5	32.7
Anastrozole	249	31.3	31.5
Ado-Trastuzumab Emtansine	57	30.0	30.2
Regorafenib	77	29.5	29.7
Goserelin	78	25.9	26.0
Everolimus	267	24.3	24.4
Abemaciclib	98	21.9	22.0
Everolimus Tablets	70	18.6	18.6
Capecitabine	351	18.1	18.1
Lapatinib	40	11.4	11.4
Gefitinib	21	10.2	10.3
Panitumumab	36	10.1	10.2
Fam-Trastuzumab Deruxtecan-Nxki	23	10.0	10.1
Zoledronic Acid	89	9.9	9.9
Trastuzumab	140	9.2	9.2
Prochlorperazine Maleate	19	9.1	9.1
Bosutinib	17	8.3	8.3
Octreotide Acetate	56	8.1	8.1
Pertuzumab	47	7.6	7.7
Sorafenib	35	7.4	7.4
Trifluridine And Tipiracil	16	6.6	6.6
Irinotecan Hydrochloride	19	6.5	6.5
Bevacizumab	174	6.4	6.4
Osimertinib	44	6.1	6.1
Zinc	33	5.9	5.9
Magnesium	108	5.9	5.9
Zinc Chloride	33	5.9	5.9
Paclitaxel	129	5.8	5.8
Human Immunoglobulin G	27	5.8	5.8
Denosumab	252	5.7	5.7
Durvalumab	26	5.6	5.6
Zinc Gluconate	33	5.6	5.6
Loperamide Hydrochloride Oral	12	5.2	5.2
Heparin Sodium	16	5.1	5.1
Paclitaxel (Aibumin-Bound)	94	5.1	5.1
Prochlorperazine	29	4.6	4.6
Loperamide Hcl	13	4.4	4.4
Dronabinol	8	4.4	4.4
Gemcitabine	38	4.3	4.3
Thiamine Hydrochloride	12	4.2	4.2
Psyllium Husk	9	4.0	4.0
Gemcitabine Hydrochloride	48	4.0	4.0
Vitamin C	78	3.8	3.8
Tramadol Hydrochloride	31	3.6	3.6
Lenvatinib	26	3.5	3.5
Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide	24	3.5	3.5
Calcium	115	3.5	3.5
Ondansetron Hydrochloride	95	3.4	3.4
Fluorouracil Cream, 0.5%	58	3.4	3.4
Fluorouracil	58	3.3	3.3
Nilotinib	22	3.3	3.3
Ondansetron	80	3.2	3.2
Ondansetron Tablets	80	3.2	3.2
Oxaliplatin	54	3.2	3.2
Benzonatate	12	3.2	3.2
Filgrastim	27	3.2	3.2
Doxorubicin Hydrochloride	23	3.1	3.1
Selinexor	6	3.0	3.0
Lisinopril And Hydrochlorothiazide	7	3.0	3.0
Biotin	21	3.0	3.0
Cisplatin	50	2.8	2.8
Lanreotide Acetate	5	2.8	2.8
Encorafenib	6	2.7	2.7
Carboplatin	75	2.6	2.6
Cabozantinib	27	2.5	2.5
Pembrolizumab	58	2.4	2.4
Pancrelipase	21	2.4	2.4
Cetuximab	17	2.4	2.4
Polatuzumab Vedotin	5	2.2	2.2
Timolol	6	2.2	2.2
Crizotinib	5	1.7	1.7
Ixazomib	11	1.7	1.7
Lutetium Lu 177 Vipivotide Tetraxetan	5	1.7	1.7
Carfilzomib	10	1.6	1.6
Vemurafenib	4	1.5	1.5
Pomalidomide	33	1.4	1.4
Remdesivir	4	1.3	1.3
Lenalidomide	87	0.9	0.9
Pegfilgrastim	19	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.